News
After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback